A5039497762- Multiple Sclerosis Research Studies
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Pharmacology and Obesity Treatment
- Immunotherapy and Immune Responses
- Systemic Lupus Erythematosus Research
- Cytokine Signaling Pathways and Interactions
- T-cell and B-cell Immunology
- Polyomavirus and related diseases
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
- Rheumatoid Arthritis Research and Therapies
- MicroRNA in disease regulation
- Advanced Breast Cancer Therapies
- Diabetes Management and Research
- Pancreatic function and diabetes
- Chemotherapy-induced cardiotoxicity and mitigation
- Neurogenesis and neuroplasticity mechanisms
- RNA regulation and disease
- RNA Interference and Gene Delivery
- Amyotrophic Lateral Sclerosis Research
- Fungal Infections and Studies
- Immune Cell Function and Interaction
- Pregnancy and preeclampsia studies
- Trauma, Hemostasis, Coagulopathy, Resuscitation
Steno Diabetes Centers
2018-2024
Novo Nordisk (Denmark)
2021-2023
Novo Nordisk (Finland)
2021
University of Copenhagen
2015
Danish Multiple Sclerosis Center
2007-2013
Rigshospitalet
2004-2013
Copenhagen University Hospital
2007-2013
Amager Hospital
2010
European Society of Anaesthesiology
2005
University of New Mexico
1984
The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people overweight or obesity is unknown.To compare continued once-weekly subcutaneous 2.4 mg, switch to placebo for (both lifestyle intervention) adults after 20-week run-in semaglutide titrated mg weekly.Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites 10 countries from June 2018 March 2020 body mass index least 30 (or...
A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment the drug adolescents has been lacking.
Background: microRNAs (miRNAs) regulate the expression of genome at post-transcriptional level. They play a role in autoimmunity and inflammation, show potential for use as therapeutic targets many diseases. With recent detection miRNAs body fluids, possibility using diagnostic biomarkers has emerged. Objective: We assessed whether contribute to altered immune activation state relapsing–remitting multiple sclerosis (RRMS) patients investigated possible (MS). Methods: performed global miRNA...
The aim of this study was to examine how improvement in BMI with the glucagon-like peptide-1 receptor agonist semaglutide translated changes category a post hoc analysis double-blind, phase 3a randomized controlled Semaglutide Treatment Effect People obesity (STEP) TEENS trial.Adolescents received once-weekly subcutaneous 2.4 mg or placebo plus lifestyle intervention, which comprised counseling healthy nutrition and goal 60 minutes moderate- high-intensity physical activity per day....
<b>Background:</b> In patients with multiple sclerosis (MS), neutralizing antibodies (NAbs) appearing during treatment interferon (IFN) β reduce or in high concentrations abolish bioactivity and therapeutic efficacy. vivo MxA induction by IFNβ is used as a marker of biologic response to IFNβ. It has been argued that despite absence measured PCR, some might be preserved. cohort study, we gene expression chip analysis NAb-negative NAb-positive test hypothesis. <b>Methods:</b> The effect was...
Numerous cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS), but studies often limited to whole blood (WB) or peripheral mononuclear cells (PBMCs), thereby omitting important information about cellular origin cytokines. Knowledge relation between and cerebrospinal fluid (CSF) cell expression source CSF is even more scarce. We studied gene a broad panel WB from relapsing-remitting (RRMS) patients remission healthy controls (HCs). Subsequently we determined...
Objective: Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)‐β. NAbs impair the effect treatment. The biological IFN‐β can be measured as induction myxovirus resistance protein A (MxA) molecule. However, other markers could more sensitive for evaluating response to IFN‐β. We used DNA array analysis identify genes that are strongly induced blood cells by IFN‐β, and their expression MS different NAb levels. Methods: Gene was...
An immune activation response resembling virus or type I interferon responses has been observed in untreated multiple sclerosis (MS), but its pathogenic significance is uncertain. We studied the relationship between a interferon-like patients with MS and disease activity.Gene expression was analyzed by real-time reverse transcriptase polymerase chain reaction (PCR) whole blood samples microarray analysis of mononuclear cells from MS, treated IFN-β, anti-IFN-β neutralizing antibodies (NAb)....
Background Multiple sclerosis (MS) affects the integrity of blood-brain barrier (BBB). Contrast-enhanced T1 weighted magnetic resonance imaging (MRI) is widely used to characterize location and extent BBB disruptions in focal MS lesions. We employed quantitative measurements before after intravenous injection a paramagnetic contrast agent assess permeability normal appearing white matter (NAWM) patients with relapsing-remitting (RR-MS). Methodology/Principal Findings Fifty-nine (38 females)...
Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established reliable indicators of response, despite substantial, biologically measurable effects. We studied the biologic response to a cohort NAb-negative test whether difference responsiveness could segregate without...
Background:Treatment with glatiramer acetate (GA) modestly decreases disease activity in multiple sclerosis (MS). The mechanism of action is incompletely understood and differences the response to treatment between individuals may exist. Objective:To study activation CD4+ T cells, monocytes dendritic cells (DC) relation MS patients treated GA. Methods:Flow cytometry was used cell subsets (CD25high CD26high cells), DCs a cross-sectional 39 untreated 29 GA-treated patients, latter followed...
Background and purpose: Neutralizing antibodies (NAbs) appearing during treatment with Interferon‐beta (IFN‐β) reduce or abolish bioactivity therapeutic efficacy. Initial combination therapy methylprednisolone (MP) may the frequency of NAb positive patients. We hypothesized that MP might also levels re‐establish IFN‐β in patients already NAb+, who discontinue therapy. Methods: In a 6‐month open‐label trial, we compared monthly high‐dose pulsed 38 Nab 35 MP‐untreated control discontinuing any...
Background: Treatment with interferon-beta (IFN-beta) increases B-cell activating factor of the TNF family (BAFF) expression in multiple sclerosis (MS), raising concern that treatment MS patients IFN-beta may activate autoimmune B cells and stimulate production MS-associated autoantibodies. Objective: To investigate whether BAFF levels are associated disease severity/activity untreated patients, to assess effect therapy on circulating anti-myelin basic protein (MBP) autoantibody levels....
Background: Glatiramer acetate (GA) treatment suppresses disease activity in multiple sclerosis (MS). The immunological response to may differ patients who are stable on GA therapy and with breakthrough activity, but the results of previous studies inconsistent. Objectives: We studied its relationship activity. Methods: Anti-GA antibodies plasma expression genes encoding cytokines T-cell-polarizing transcription factors blood cells were analysed by flow cytometric bead array polymerase chain...
Autoreactive CD4+ T-cells are considered to play a major role in the pathogenesis of multiple sclerosis. In experimental autoimmune encephalomyelitis, an animal model sclerosis, exogenous and endogenous type I interferons restrict disease severity. Recombinant interferon-β is used for treatment some untreated sclerosis patients have increased expression levels interferon-inducible genes immune cells. The controversial: studies found association high interferon-β-inducible with interleukin-10...
What is this summary about? This a plain language of the STEP TEENS research study, which was originally published in New England Journal Medicine . As more teenagers are living with obesity than ever before, researchers searching for new treatments. first study looking at how well medicine semaglutide works as treatment teenagers. were results? In looked effect on body mass index (BMI) and weight loss compared to dummy (placebo). A 17% decrease BMI reported treated placebo. For loss, an 18...
It is unknown whether immunosuppression of patients who have developed interferon-beta (IFN-beta) neutralizing antibodies (NAbs) hastens disappearance NAbs in the blood.We wanted to test with cyclic methylprednisolone (MP) combination azathioprine (AZA) for 6 months accelerates recovery IFN-beta bioactivity multiple sclerosis (MS) abolished in-vivo myxovirus resistance protein A (MxA) mRNA response IFN-beta.We included 13 MS and a low bioavailability detected by MxA-mRNA descriptive,...
Brief summary: This phase 3 double-blind, parallel-group, randomized, placebo-controlled trial over 68 weeks randomised (2:1) 201 adolescents with obesity to receive semaglutide 2.4 mg once weekly or placebo. Both groups also received lifestyle intervention. The primary endpoint was the percentage change in BMI. Treatment produced clinically relevant reductions BMI and body weight, improvements cardiovascular risk factors, which were all significantly greater than control group\.
Abstract Background: Inflammation-associated proteinuria in acute, nonrenal disease is a common but poorly understood phenomenon. We performed an observational study of the urinary excretion orosomucoid (α1-acid glycoprotein), albumin, α1-microglobulin (protein HC), and IgG to obtain quantitative temporal data on these 4 proteins. Methods: Urine samples were collected at daily intervals for up 23 days from 6 patients with surgery-induced inflammation hourly 24-h period 7 sepsis patients....
Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease activity, role endogenous IFN in MS remains controversial. We studied CD4+ T cells and cell subsets, monocytes dendritic by flow cytometry analysed relationship IFN-like effect therapy, clinical magnetic resonance imaging (MRI) activity patients. Endogenous was associated decreased expression integrin subunit CD49d (VLA-4) on CD4+CD26high (Th1 helper cells), this less MRI activity. therapy...
Abstract Background: Semaglutide is a long-acting, subcutaneous (s.c.), glucagon-like peptide-1 analogue that currently being investigated for obesity management in adults with overweight or the phase 3 STEP clinical trial program. Varying degrees of weight loss were observed once-weekly s.c. semaglutide 2.4 mg 1, and post-hoc analysis was conducted to investigate subgroups participants based on their baseline characteristics. Methods: 1 randomized, double-blind, placebo-controlled,...
The migration and concentration of lymphocytes at sites antigenic challenge are an integral part the expression delayed cutaneous hypersensitivity, as well tumor graft rejection. In this study, we have analyzed T from patients with malignancy. We used casein concanavalin A (Con A)-stimulated mononuclear cell supernatants to stimulate locomotion. Peripheral blood 30 established malignancy, 10 indolent malignancy or benign tumor, 42 normal adult controls were tested. Data expressed a index...